Angiotensin II receptor antagonist (Telmistartan 80mg/day) vs placebo | Right Decisions

Right Decisions
Polypharmacy guidance: realistic prescribing
Efficacy (NNT)
By Condition
Back
Heart Failure
Angiotensin II receptor antagonist (Telmistartan 80mg/day) vs placebo

Update your RDS mobile app to v4.7.2 to download toolkits even when website is down.

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. You will see that each toolkit has a small QR code icon in the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively update to the latest release - RDS app version 4.7.1 - to see this improvement.

Updating to this latest version of the RDS app is also strongly recommended to get the full benefits of the new resilience arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Study population:

Patients intolerant of ACE Inhibitors with:

established cardiovascular disease:

Coronary artery, peripheral vascular or cerebrovascular disease, or diabetes with end organ damage

Patients with heart failure were excluded.

Comments:

Mean age of patients was approx. 67 years.

Death rate (of any cause) was higher in treatment group than placebo group. When hospitalisations for cardiac failure were added to the composite endpoint as a primary outcome, the results were non-significant. Study concluded that telmisartan did not significantly reduce cardiovascular death.

Outcome	Duration	NNT	Annualised NNT
Prevent one of a composite of cardiovascular death, MI or stroke.	56 months (median duration of followup)	55	258

References

Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet. 2008; 372: 1174-1183